Fig. 5: Pharmacologic inhibition of the tuft cell-ILC2 circuit reduces gastric tumor growth.

a Schematic outline of the antibody-mediated blockade of IL13 or IL25. 13-week-old mice were treated with either α-IL13, α-IL25 or a matched IgG isotype control (300 μg/20 g mouse, once weekly for 3 weeks). Mice were culled one week after the third injection. EP = endpoint. b Representative images of gp130^F/F stomachs treated as described in Fig. 3a. Dotted circles indicate tumors. Scale bar = 8 mm. c Tumor mass of gp130^F/F mice following treatment with α-IL13 or a matched IgG isotype control. N = 6 and 6 respectively. d Tumor mass of gp130^F/F mice following treatment with α-IL25 or a matched IgG isotype control. N = 6 and 6 respectively. e IHC staining and quantification of DCLK1⁺ tuft cells in α-IL13 and IgG treated gp130^F/F mice. Scale bar = 300 μm. N = 6 and 6 respectively. f IHC staining quantification of DCLK1⁺ tuft cells in α-IL25 and IgG treated gp130^F/F mice. Scale bar = 300 μm. N = 6 and 7 respectively. g Flow-cytometry quantification of KLRG1⁺CD90.2⁺Lineage⁻ CD45⁺ ILC2s in tumors of gp130^F/F mice treated with α-IL13 or a matched IgG isotype control. N = 6 and 6 respectively. h Immunofluorescence (IF) staining and quantification of Gata3⁺CD3^- ILC2s in tumors of gp130^F/F mice treated with α-IL25 or a matched IgG control. Arrows indicate ILC2s. Scale bar = 100 μm. N = 5 and 5 respectively. Data represents mean ± SEM, p values from two-sided Student’s t-test *p < 0.05, **p < 0.01, ***p < 0.001. Each symbol represents an individual mouse. Data is from two pooled experiments. Source data and exact p values are provided as a Source Data file.